Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D, Jais JP, Desablens B, Berthou C, Casassus P, Moles MP, Delwail V, Gastinne T, Colonna P, Andrieu JM. Sénécal D, et al. Among authors: jais jp. Cancer. 2008 Feb 15;112(4):846-55. doi: 10.1002/cncr.23247. Cancer. 2008. PMID: 18072259 Free article.
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, Quittet P, Jais JP, Colonna P, Andrieu JM; Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang. Arakelyan N, et al. Among authors: jais jp. Cancer. 2008 Dec 15;113(12):3323-30. doi: 10.1002/cncr.23979. Cancer. 2008. PMID: 18988286 Free article. Clinical Trial.
Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
Arakelyan N, Jais JP, Delwail V, Brière J, Moles-Moreau MP, Sénécal D, Berthou C, Desablens B, Colonna P, Andrieu JM; GOELAMS Hodgkin Lymphoma Network. Arakelyan N, et al. Among authors: jais jp. Cancer. 2010 Sep 1;116(17):4054-62. doi: 10.1002/cncr.25295. Cancer. 2010. PMID: 20564152 Free article. Clinical Trial.
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM. Arakelyan N, et al. Among authors: jais jp. Leuk Lymphoma. 2013 Jan;54(1):76-82. doi: 10.3109/10428194.2012.701737. Epub 2012 Jul 9. Leuk Lymphoma. 2013. PMID: 22680774 Clinical Trial.
Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients.
Nielsen L, Canouï-Poitrine F, Jais JP, Dahmane D, Bartolucci P, Bentaarit B, Gellen-Dautremer J, Remy P, Kofman T, Matignon M, Suberbielle C, Jacquelinet C, Wagner-Ballon O, Sahali D, Lang P, Damy T, Galactéros F, Grimbert P, Habibi A, Audard V. Nielsen L, et al. Among authors: jais jp. Br J Haematol. 2016 Jul;174(1):148-52. doi: 10.1111/bjh.14040. Epub 2016 Mar 17. Br J Haematol. 2016. PMID: 26992059 Free article.
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, Salles G, Henry-Amar M. Mounier N, et al. Among authors: jais jp. Cancer. 2019 Jul 1;125(13):2291-2299. doi: 10.1002/cncr.32040. Epub 2019 Mar 22. Cancer. 2019. PMID: 30901086 Free article.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Le Gouill S, et al. Among authors: jais jp. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. Blood. 2021. PMID: 33211799 Free article.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Récher C, et al. Among authors: jais jp. Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4. Lancet. 2011. PMID: 22118442 Free article. Clinical Trial.
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P. Copie-Bergman C, et al. Among authors: jais jp. Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15. Blood. 2015. PMID: 26373676 Free article. Clinical Trial.
231 results